Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

Jun 25, 2026

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 12, 2026

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

See More Press Releases

The Conversation (0)

Alert Options

No alert set

INN Article Notification

Instant Daily Weekly

Alert Option

You will be notified when this event occurs. No additional settings needed.